Two independent ataxic individuals carry the same de novo Pro512Leu mutation in CAPRIN1
Affected individual II.3 of family A was referred for genetic counseling at the age of 10 years because of the development of gait abnormalities and muscular weakness. She was born to non-consanguineous parents of Turkish descent and had two older healthy siblings (Fig. 1a). Her symptoms worsened over the following years, with trunk instability and scoliosis leading to her being first confined to a wheelchair and later to a bed. The motor deficits were accompanied by bulbar symptoms (dysphagia and dysarthria), concentration anomalies, social withdrawal and cognitive decline (IQ 64). Standard laboratory and metabolic tests were negative. Muscular biopsy revealed neurogenic fiber atrophy and magnetic resonance imaging (MRI) at 16 years of age displayed cerebral and cerebellar atrophy (Fig. 1b). Deletions of SMN1 were excluded and no causative variant was found using an in-house NGS gene panel covering 62 genes associated with lower motor neuron disorders [29].
Affected individual II.2 of family B was born to non-consanguineous parents of Italian descent and had a healthy sister (Fig. 1a). He articulated his first words with slight phonetic problems and presented with dysarthria at the age of 4 years. At the age of 7 years, he developed slowly progressive ataxia and learning difficulties (IQ: 77). By the age of 11 years, his trunk stability worsened and standing up became more difficult. At the age of 12 years, MRI showed global cerebellar atrophy (Fig. 1b). At the age of 13 years, he showed increased muscle fatigue and muscle hypotrophy, with absent deep tendon reflexes in all four limbs. He also became increasingly anxious, but improved with psychotherapy. Standard laboratory and metabolic tests were negative. Somatosensory evoked potentials (SSEPs) were reduced in the lower limbs.
Both affected individuals and the respective parents (A-I.1, A-I.2, A-II.3, B-I.1, B-I.2, B-II.2) were subjected to trio whole exome sequencing. Variant filtering followed standard metrics (quality, allele frequency < 0.01 in gnomAD; Note S1). Variants were prioritized assuming an autosomal recessive model of inheritance or a de novo mutation occurrence. The c.1535C > T (NC_000011.10:g.34090659C > T, exon 14, p.Pro512Leu) CAPRIN1 (GenBank: NM_005898.5) variant resulted as the most likely candidate in both families: this variant was absent in gnomAD [30], affects a highly conserved residue and was predicted to be deleterious by multiple scores (CADD PHRED score: 29.8; SIFT: 0 [deleterious]; PolyPhen-2: 0.993 [probably damaging]) (Fig. 1c-e) [31, 32]. In addition, the likelihood that the same de novo variant occurs in two independent individuals is extremely rare (1 in 154 million, Note S2).
Several other characteristics support the involvement of CAPRIN1 as a neurodegeneration-causing gene: (i) CAPRIN1 is highly expressed in the human and murine central nervous system, and in particular in cortex and cerebellum [3, 4]; (ii) CAPRIN1 is a RBP harboring a PrLD (Fig. 1f and 1g) [2, 7], feature shared by many ND-linked genes [10]; (iii) CAPRIN1 is a component of SGs [6], whose role in NDs is well documented [33]; CAPRIN1 is an interacting partner of ATXN2 and GEMIN5 [34, 35], whose pathogenic variants are associated with ataxia [36, 37], and FMR1 (Fig. 1f) [13], a protein associated with fragile X tremor/ataxia syndrome (FXTAS) [38].
In silico CAPRIN1P512L modeling predicts increased aggregation propensity
Since mutations linked to NDs in PrLD-containing proteins cause increased protein misfolding and the P512L substitution occurs close to the PrLD (Fig. 1f) (residues 537–709) [19, 39–42], we hypothesized that it would render CAPRIN1 prone to misfolding and aggregation. Indeed, in silico analysis of CAPRIN1 and CAPRIN1P512L using the PLAAC, CamSol and ZipperDB tools predicted an increase in aggregation propensity and an increase in protein insolubility for CAPRIN1P512L (Fig. 1h, 1i and S1a) [17, 18, 43].
CAPRIN1P512L forms insoluble aggregates
To investigate the potentially increased aggregation propensity of CAPRIN1P512L, we overexpressed V5-tagged CAPRIN1 and CAPRIN1P512L in HEK293T cells and sequentially extracted proteins from a more soluble (RIPA) and less soluble (urea) fraction. CAPRIN1-V5 was mainly eluted in the RIPA-soluble fraction, while CAPRIN1P512L-V5 exhibited reduced solubility and was recovered in the urea-soluble fraction (Fig. 2a), a behavior found in other mutant PrLD-containing proteins related with degenerative disorders [20].
Remarkably, in SH-SY5Y cells, overexpression of EGFP-tagged CAPRIN1 mostly revealed diffuse cytoplasmic localization and coalesces in small round clusters (Fig. 2b and S1b), compatible with the induction stress granules, as previously reported [2, 6]. On the contrary, EGFP-CAPRIN1P512L mostly formed few, large aggregates (Fig. 2b-d, 3a-d and S1b-d).
CAPRIN1P512L aggregates are positive for typical NDs markers
Since protein misfolding and impairment of the protein quality control (PQC) are widely recognized pathomechanism of NDs [44], we investigated protein homeostasis markers, such as ubiquitin and p62. Under physiological conditions, the formation of aggregates is prevented by the activity of molecular chaperons of the PQC, which are also able to unfold misfolded proteins. When folding is not possible, misfolded proteins are ubiquitinated by E3 ubiquitin ligases and directed to proteasomal degradation via the ubiquitin-proteasome system (UPS) [45, 46]. Indeed, bulky CAPRIN1P512L aggregates were positive for ubiquitin (Fig. 2c). Moreover, since insoluble aggregates can inhibit the 26S proteasome and be targeted for lysosomal degradation by macroautophagy [47, 48], we stained CAPRIN1P512L aggregates for p62/SQSTM1 positivity and we could indeed detect a strong signal, as reported for other NDs (Fig. 2d) [49]. Taken together, these results suggest that CAPRIN1P512L misfolds and becomes targeted for degradation.
CAPRIN1P512L aggregates sequester ataxia-related proteins
We next investigated if CAPRIN1P512L inclusions sequester other proteins, resembling the pathophysiology of other age-related neurodegenerative disorders: for example, α-synuclein (SNCA) inclusions (Lewy bodies) can be found in Parkinson’s disease (PD) and Lewy bodies dementia (LBD) [50]. Likewise, TARDBP aggregates are a common feature in both amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) pathology despite their genetic heterogeneity [51, 52]. CAPRIN1 has also been detected in aggregates in TARDBP or FUS-positive ALS spinal cord motor neurons [34, 53, 54]. We detected a strong SNCA positivity for CAPRIN1P512L aggregates (Fig. 3a, Table 1), but no colocalization with TARDBP and FUS (Fig. S1c and S1d).
Table 1
Pearson’s correlation coefficients for colocalization
| CAPRIN1 | CAPRIN1P512L | p-value |
Ubiquitin | 0.07 ± 0.09 | 0.71 ± 0.17 | *** |
p62 | 0.39 ± 0.09 | 0.69 ± 0.17 | ** |
SNCA | 0.34 ± 0.14 | 0.89 ± 0.12 | *** |
ATXN2 | 0.43 ± 0.07 | 0.75 ± 0.02 | *** |
GEMIN5 | 0.40 ± 0.07 | 0.81 ± 0.22 | ** |
SNRNP200 | 0.11 ± 0.06 | 0.94 ± 0.03 | *** |
*: p < 0.05, **: p < 0.01, ***: p < 0.001 |
We next examined whether CAPRIN1P512L aggregates would sequester other known CAPRIN1 binding partners. We focused on specific candidates: ATXN2, whose polyQ expansions cause spinocerebellar ataxia 2 (SCA2) [36], and GEMIN5, whose biallelic mutations cause neurodevelopmental delay and ataxia [37]. Indeed, both proteins were present in the CAPRIN1P512L inclusions (Fig. 3b and 3c; Table 1).
Due to the progressive muscular atrophy of the affected individuals, we additionally investigated if the aggregates contained SNRNP200, another CAPRIN1 interacting partner that has been reported in the cortical and spinal motor neurons of ALS cases and indeed we could detect it (Fig. 3d; Table 1) [35]. Taken together, these results indicate that CAPRIN1P512L inclusions are able to sequester multiple ND and ataxia-related proteins.
CAPRIN1P512L iPSC-derived neurons show reduced neuronal activity
To study the effects of the P512L substitution in a human neuronal cell model, we generated the heterozygous CAPRIN1WT/P512L and the homozygous CAPRIN1P512L/P512L isogenic cell lines from the CAPRIN1WT/WT HUVEC iPSC line using CRISPR/Cas9 genome editing (Fig. S2a). We then differentiated them in cortical neurons using the protocol from Schuster et al, 2020 (Fig. S2b and S2c). These iPSC-derived neurons do not show any significant change in CAPRIN1 levels at neuronal maturation (D36), nor any overt morphological alteration of the cell soma or the neurites (Fig. 4a).
In particular, both iPSCs and iPSC-derived neurons harboring the CAPRIN1P512L mutation did not display any protein aggregates, even upon proteasomal inhibition (Fig. S3a-b and S4a). Their absence, however, is reported for many other iPSC-derived neuronal cells lines that harbor mutations associated with protein aggregation in tissue sections from individuals suffering of ataxia, Parkinson’s disease or Huntington’s disease (HD) [55–57].
Since in several disease models electrophysiological changes in neurons precede neuronal loss [58], we recorded the spontaneous neuronal activity using a microelectrode array system. Interestingly, while CAPRIN1WT/WT and CAPRIN1WT/P512L neurons increased their firing rate upon maturation, CAPRIN1P512L/P512L neurons showed a clearly reduced spike rate and almost no bursting throughout the whole recording period (Fig. 4b-e). On the other hand, after an initial overlap, also the activity of CAPRIN1WT/P512L neurons progressively decreased (Fig. 4b-e).
CAPRIN1P512L iPSC-derived neurons show impaired stress granules dynamics
Since CAPRIN1 represents one of the main components of SGs [6, 11], and disease-linked mutations in TDP-43, FUS or C9ORF72 cause an increase of cells presenting SGs upon stress [59–61], we hypothesized that the CAPRIN1P512L mutation could alter their dynamics. Therefore, we treated the iPSC-derived neurons with sodium arsenite (SA), a common SG inducer [6], and studied their resolution at different time points. Intriguingly, upon SA treatment, a higher fraction of CAPRIN1WT/P512L neurons showed SGs in comparison to both CAPRIN1WT/WT and CAPRIN1P512L/P512L neurons (Fig. 5a and b). Moreover, in CAPRIN1WT/P512L neurons the resolution of the SGs occurred slower than in the other cell lines, resulting in the persistence of SG for a longer time after stress removal. Strikingly, this difference could not be observed in CAPRIN1P512L/P512L neurons, where the SGs resolution tended to be even faster than in the CAPRIN1WT/WT neurons, suggesting a more complex scenario where the CAPRIN1 properties and interactions might play a major role.
CAPRIN1P512L adopts an extended conformation
To investigate whether the P512L mutation influences CAPRIN1 structure, we characterized recombinantly produced and purified mGFP-CAPRIN1 and mGFP-CAPRIN1P512L (Fig. 6a). We used nano-differential scanning fluorimetry (nanoDSF) to monitor the tertiary structure and unfolding transitions of CAPRIN1. This revealed significant differences in the fluorescence ratio (F350/F330) at 20°C and an increased stability of mGFP-CAPRIN1P512L in comparison to mGFP-CAPRIN1 (Fig. 6b, Table 2). These data suggest that the mutation does not cause a substantial destabilization of the protein and that the two proteins have a similar tertiary structure. Dynamic light scattering (DLS) and fluorescence correlation spectroscopy (FCS) measurements showed that mGFP-CAPRIN1P512L exhibits an increased hydrodynamic radius compared to that of mGFP-CAPRIN1 (Fig. 6c, Table 2). Taken together, the data suggest that CAPRIN1P512L adopts an extended yet near native conformation.
Table 2
Biochemical properties of mGFP-CAPRIN1 and mGFP-CAPRIN1P512L
| CAPRIN1 | CAPRIN1P512L | p-value |
Ratio, 20°C (F350/330)a | 0.84 ± 0.006 | 0.86 ± 0.009 | ** |
Tm (°C)b | 47.8 ± 0.1 | 48.4 ± 0.1 | *** |
Radius (FCS, nM) | 4.8 ± 0.5 | 5.8 ± 0.2 | * |
*: p < 0.05, **: p < 0.01, ***: p < 0.001 |
a: F350/F330 fluorescence ratio at 20°C; b: unfolding temperature. |
The P512L mutation does not impair CAPRIN1 dimerization
Given the differences in hydrodynamic radius between CAPRIN1 and CAPRIN1P512L and the ability of CAPRIN1 to form dimers [12], we used FCS to test for changes in CAPRIN1 oligomerization. We measured the brightness of mGFP-CAPRIN1 and mGFP-CAPRIN1P512L and compared it to the brightness of free GFP. Both proteins were shown to associate into dimers in solution even at concentrations as low as 50 nM (Fig. 6d). Consistent with the formation of CAPRIN1 dimers, the GFP brightness decreased when mGFP-CAPRIN1 was mixed with an excess of unlabeled CAPRIN1, demonstrating the formation of spectroscopic heterodimers (Fig. S5a). In accordance with the distance between the mutated residue and the annotated dimerization domain (residues 132–251) [12], our data demonstrate that the P512L mutation does not affect dimerization, but rather results in an expanded conformation of the protein.
CAPRIN1P512L aggregation is enhanced by RNA
Since CAPRIN1 is an RBP, we examined whether this conformational change would alter its affinity for RNA. To this end, we incubated CAPRIN1 with ATTO590-labelled single stranded RNA (ssRNA). CAPRIN1P512L showed reduced RNA affinity (KDCAPRIN1: ~506 ± 223 nM; KDCAPRIN1−P512L: ~947 ± 239 nM; Fig. 6e). We then tested the reversibility of the CAPRIN1-RNA interaction by adding unlabeled long homopolymeric polyA RNA as a competitor. In accordance with the previous data, CAPRIN1 binds ssRNA ~ 2-fold tighter than CAPRIN1P512L (KICAPRIN1: 60.5 ± 0.7 ng/µl; KICAPRIN1−P512L: 33.5 ± 12 ng/µl; Fig. 6f).
To further investigate CAPRIN1P512L properties, we observed mGFP-CAPRIN1 and mGFP-CAPRIN1P512L by fluorescence microscopy. While mGFP-CAPRIN1 displayed a diffuse signal, mGFP-CAPRIN1P512L formed small agglomerates, confirming the increased aggregation propensity seen in our cell models (Fig. 6g). Since CAPRIN1 is a RBP and recent studies demonstrated the pivotal role of RNA in the modulation of protein aggregation [62, 63], we next incubated the purified proteins with RNA. Strikingly, while mGFP-CAPRIN1 remained soluble, mGFP-CAPRIN1P512L formed large, microscopically visible aggregates (Fig. 6g). This effect was independent of the RNA type, and all RNA types tested caused aggregation of mGFP-CAPRIN1P512L (Fig. S5b). Since the association of RBPs with nucleic acids is often driven and stabilized through electrostatic interactions, we increased the salinity after complex formation to distinguish weaker (reversible) from stronger (irreversible, indicative of aggregates) interactions. Increasing the salinity reduced the degree of aggregation only to some extent, and addition of RNase A did not dissolve the aggregates (Fig. 6g). This suggests that CAPRIN1P512L misfolding might be triggered by RNA, but that RNA is not necessary for aggregate persistence. Consistent with this, our FISH analysis in CAPRIN1P512L transfected cells showed that the formed aggregates do not contain polyA RNA (Fig. S5c).
Taken together, these data indicate that the Pro512Leu mutation alters the dynamics of binding to RNA which might influence the aggregation propensity of CAPRIN1.